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Abstract
Background: The chiropractic profession emerged when scientific explanations for causes of health and disease were
still in infancy and the co-existence of notions such as innate healing and vitalism were perhaps admissible within such a
historical context. Notwithstanding, within the scientific culture of the 21st Century all healthcare paradigms require
evidential support which in regard these early concepts are in large part, absent. Nevertheless, a large body of emerging
scientific evidence supports the existence of innate healing phenomena that may explain a plethora of clinical outcomes
observed during chiropractic care. However, in contrast to the notion that removing the putative subluxation constitutes
the mechanism by which this healing is initiated, the evidentially supported explanation is one that invokes the impact of
contextual factors inherent in the skilful care and authority of the healthcare provider. This perspective is presented here
as the scientific model of Contextually Aided Recovery (CARe).
Main body: This paper contends that;
1. Contextual effects are powerful and desirable and are triggered by contextual factors present in all therapeutic
encounters including those encountered in chiropractic practice.
2. These factors can elicit large clinical effects with substantive evidence supporting pain, immune and motor
modulation.
3. The compartmentalisation of specific and non-specific effects is a biologically and scientifically false dichotomy,
erroneously invoked to de-legitimise treatment approaches that expertly construct contextual healing scenarios.
4. The use of factors to construct contextual healing scenarios that maximise positive (placebo) and minimize negative
(nocebo) effects is a skilful clinical art within the multimodal approach that describes modern chiropractic care and
should be presented and defended as a legitimate component of orthodox healthcare
Clinical improvement during chiropractic care, beyond any biologically specific treatment effects of manipulation and
other modalities, may be largely understood considering contextual factors as described by a Contextually Aided
Recovery (CARe) model.
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Introduction
In 1644 Descartes formulated the idea that the mind and
the body are made of distinct and separate substances;
extended matter (body) and non-extended matter (mind
or soul). This Cartesian dichotomy went on to form the
basis of a persistent paradigm where the separation of
mind and body became embedded in Western thought
[1]. Some historians have seen this split as a necessary
solution of freeing science from religious dogma in that
scientists were excluded from questions of the soul or
mind but could progress with exploration of the bio-
logical machine as represented by the body This enabled
the wresting of the body from the sanctity and protec-
tion of religion and offered it up to science and medicine
for investigation [2]. Subsequent to this, the medical
paradigm has continued to tacitly characterize the legit-
imacy of treatment interventions within this framework,
exemplified by such terms as psychosomatic, to describe
what are seen as somewhat illegitimate complaints due
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to the dominance of the mind in the symptomatology as
compared to the body [3].
Although much progress has been made, illustrated by
the rise of the biopsychosocial [4] and patient centered
model of care [5], the perception that health and illness
are predominantly associated with the body persists as a
recent survey of both university students, healthcare
workers and the lay public reported [6].
In the last decade or so, mounting evidence has begun
to elucidate mechanisms that underlie some of the so
called specific effects of spinal manipulative therapy as
they pertain to improvements in musculoskeletal symp-
tomatology [7–12]. In addition, mechanisms underlying
so called non-specific effects are increasingly being char-
acterised and not only blur the line between the notion
of specific and non-specific but go deep to the entire de-
scription of what constitutes legitimate treatment not
only within CAM but at the heart of medical practice it-
self [13]. Recent articles have already outlined this bur-
geoning area of scientific endeavour and its potential
impact within manual therapeutic approaches [14, 15],
arising as it does from increasingly detailed neurophysio-
logical mechanisms describing the role of the placebo
effect in clinical practice. This article aims to articulate
an evidential explanatory framework that presents the
imperative of these powerful therapeutic factors. In
addition, and in contrast to the historical negativity
associated with the language of placebo we also intro-
duce a new descriptive model called Contextually
Aided Recovery (CARe).
The loading of language: from placebo to CARe
Placebo has a bad name and always did. Emerging as it
probably did from medieval Europe it referred to the
practice of paid mourners who came to ‘crocodile cry’ at
the funeral of someone they didn’t know. Further en-
trenchment of its charlatan nature over the years led to
it being used in general to describe allegations of fraudu-
lent duping of clients most often in medicine with its
plethora of potions, pills and snake oils [16]. At the end
of the 19th Century, Mesmer [17] became associated
with the therapeutic use of magnetism, a newly de-
scribed scientific phenomena which he used to ‘cure’
various ailments and illnesses. A famous experiment and
an early forerunner of the clinical trial had a practicing
associate of Mesmer magnetize one of four trees leaving
the others untouched. A sickly and blindfolded boy was
then asked to approach the trees and decide which were
magnetized. Needless to say, given the expectation and
tension the boy convulsed at every tree becoming more
affected as he distanced himself from the truly magne-
tized tree. This led to the idea that a mere ‘placebo’ ef-
fect generated purely in the head of the patient, was
responsible for the patient reported therapeutic effects.
Although Mesmer himself fell quickly out of favour, the
practice survived for many years providing devotees with
healthy businesses ‘curing’ many ills and maladies with
the use of magnetism.
In the light of recent advances in understanding, the
often-heard dismissal of the legitimacy of some patient
complaints, ‘it’s all in your head’ was somewhat nearer to
the truth than perpetrators of such Cartesian dualism
knew [18]. However, such separation of the influence of
the mind on the body with thought, being limited in its
ability to directly influence physiology, persisted. Fur-
thermore, there remained much scepticism amongst the
medical profession at large who preferred to deal with
the physical ailment itself rather than the mind that was
attached to it [19].
Placebo then came to represent ‘nothing’, an inert in-
gredient with no effect and often with fraudulent over-
tones attached. This idea is correct in that most
placebos are indeed inert and do not have an effect gen-
erated by the specific ingredient they are made of. For
example, it is not the chalk or the sugar in a placebo pill
that interacts in some molecular way with pain receptors
to generate common and powerful placebo analgesic
effects but rather the patient’s own central nervous sys-
tem (CNS) that generates the analgesia [20]. Here then,
the placebo pill or intervention is merely a trigger,
wrapped in contextual meaning that initiates an innate
ability of the CNS to directly modulate ascending noci-
ception. Although placebo analgesia is the most studied
phenomenon it appears it is not the only physiological
system that the human CNS can modulate via conscious
cues. Evidence is now incontrovertible that patient ex-
pectation of benefit as constructed by the use of such
contextual cues can also powerfully modulate motor and
immune function.. For example, in motor function pla-
cebo administration can have marked effects on per-
formance [21, 22] and giving placebo antihistamines to
patients with dust mite allergy serves to significantly re-
duce allergic symptoms merely through expectation of
an effect on the part of the patient [23]. Similarly, sig-
nificant modulation of psoriasis can be achieved through
the administration of placebo [24], as can supposed
functional conditions such as irritable bowel syndrome
(IBS) and other gastrointestinal problems, leading some
authors to suggest that “Rather than focusing on a ‘per-
sonalized’ choice of drugs based on biomarkers or genes,
it might be the doctor–patient communication that needs
to be tailored” [25]. An increasing realization and evi-
dence base that show powerful modulation of previously
considered automatic processes is emerging, as gener-
ated by the patient given the right context and expect-
ation. These effects are clinically substantive, widespread
and not something to be underestimated. Some authors
have suggested alternative language to describe this
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phenomenon to decouple the historically negative
semantics of placebo from what are ostensibly desirable
effects. For example, Moerman suggested the ‘meaning
effect’ [26] while ‘contextual effect’ or ‘contextual heal-
ing’ have also been suggested [27]. The contextual effect
- i.e., the analgesia, modulated immune or motor re-
sponse - can be triggered by a raft of contextual factors
commonly present in therapeutic encounters. These may
include administration of a pill or treatment, powerful
words as used by a clinician, the clinical environment it-
self or the cultural signals engendered by the use of a
white coat or the title of “doctor” amongst many others
[28]. A recent review included general categories of
known factors that support contextual healing; patient-
physician relationship (verbal communication, nonverbal
communication), treatment features (clear diagnosis,
overt therapy and observational learning, patient centred
approach, global process of care, therapeutic touch), and
healthcare setting features (environment, architecture
and interior design) [29]. Contextual factors then are
components of the clinical encounter that appear to
provide triggers for the contextual effect, i.e., the reduc-
tion of symptoms or improvement in the condition.
Construction and delivery of contextual factors is not
trivial. It requires skill and knowledge on the part of the
heath care provider. If carried out incorrectly, contextual
factors can cause equally powerful exacerbation of the
symptoms or disease process, otherwise known as
nocebo [30]. Indeed, the aboriginal tradition of pointing
the bone along with social exclusion have been known
to be correlated with the actual demise of the individual,
and could potentially be seen as an example of extreme
nocebo [31]. In this respect the use of CARe as a thera-
peutic model can be both clinically beneficial if delivered
well and harmful if not. In this context therefore it is in-
distinguishable from descriptions of other legitimate
therapeutic interventions.
The neurophysiology of contextually driven
modulation of pain, immune and motor function
Pain
The characterisation of the neural mechanisms that
underlie the contextual modulation of pain in humans
has been extensively described [32, 33]. The elements
that trigger such effects within manual therapeutic clin-
ical encounters are also emerging [29]. The ability of in-
dividuals to innately attenuate the sensation of pain is
significant and can be equivalent to up to 8 mg of mor-
phine administered intravenously [34, 35]. These effects
have repeatedly been measured in clinical trials designed
to determine the analgesic effects of pain relieving phar-
maceuticals. Indeed, the placebo arm of such trials is
there precisely to measure such effects. In the case of
low back pain trials, the effects of several common
pharmaceuticals have been shown to be no greater than
a placebo [36, 37]. Even in the use of classic opioid
drugs, effects are short term, and for chronic low back
pain evidence of efficacy is scant [38]. In addition, there
is a considerable risk of addiction and harm associated
with their use [39, 40]. The fact that the effect of both
the placebo and the drug can be very significant com-
pared to no treatment is often not highlighted in the in-
terpretation of such trials where what is highlighted is
any substantive difference in effectiveness between the
drug and the placebo which is often small or absent.
However, if an administration of placebo can reduce
pain by statistically and clinically significant amounts in
multiple trials in comparison to common analgesic
drugs, then why aren’t health care professionals who see
patients in pain, not capitalising on the ability of such
mechanisms to help manage such pain for their patients,
particularly when the use of common analgesic drugs
are accompanied by risk of serious side effects [41, 42].
Despite ethical issues surrounding deception [13, 43, 44],
including the efficacy of open placebos where the patient
knows the intervention is inert [45], the language of
clinical trials continues to centre on the elimination
of the placebo effect with highlighting any extra effect
of the drug or intervention, the specific effect, being
the central goal. However, where the placebo effect is
large and clinically significant the idea of eliminating
the benefits of such a phenomenon outside of clinical
trials appears nonsensical.
What then is the ingredient that generates the placebo
based modulation of pain? Evidence is now overwhelm-
ing indicating it to be the patients’ own CNS within
which specific identifiable neural pathways are triggered
by contextual factors within the clinical encounter.
These are real, physical, measurable and clinically signifi-
cant effects with numerous studies having now compre-
hensively documented such analgesic effects and the
neural pathways that generate them [33, 46–50]. Such
studies have shown that contextually modulated anal-
gesia is controlled by a set of anatomically and function-
ally identifiable neural pathways that involve a range of
specific neurotransmitters including endorphins, chole-
cystokinin, dopamine and anandamide. Generally, these
pathways connect paleo-biologically modern cortical
processes (underlying conscious awareness of complex
social cues) to ancient brain stem modulation of ascend-
ing and descending nociceptive spinal pathways via con-
nections with emotional and reward systems [51–53].
This modulation can both enhance (nocebo) and attenu-
ate (placebo) pain, based on the meaning to the patient
of contextual factors present within a clinical encounter.
Present knowledge suggests the interpretation of the
meaning of these factors in the context of the patient's
understanding appear to operate through psychological
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mechanisms such as expectation and classical condition-
ing as do the other marked effects outside of pain modu-
lation documented below. In short, how a patient
understands and interprets the words and actions of a
clinician and the clinical environment within a clinical
encounter can switch on or off neurobiological pathways
that directly reduce or enhance pain.
Immune function
The impact of CNS modulation on immune function is
not as well characterised as that describing analgesia.
However, studies are increasingly documenting the ef-
fects of both expectation and classical conditioning as
triggered by contextual factors in clinical encounters
across a range of immune based health conditions. This
emerging evidence is beginning to illuminate the mecha-
nisms involved in connecting immune function with
higher cognitive processes. For example, studies have
shown that placebo antihistamine can markedly reduce
symptoms in a range of allergies if administered under
conditions that elicit expectation of effect as signalled by
clinical context [54]. These effects do not seem to be
limited to self-reported symptoms in that cellular
changes in immune cell counts and activity can be mea-
sured if classical conditioning is involved (i.e., pairing an
inert signal such as novel tasting drink with immuno-
suppressive drug) [55]. Indeed, such conditioning has
been suggested as a new therapeutic approach in redu-
cing immunosuppressive drug dose by harnessing the
innate ability of neural-immune system communication
to learn an effective placebo [56].
Like placebo induced analgesia, this evidence suggests
that conscious interpretation of context, and the mean-
ing this has for the patient, can be used by the CNS to
actively modulate immune processes down to the cellu-
lar level. Very recent studies have provided insights into
the ‘hardware’ conduit of this connection between the
CNS and the immune system with reports suggesting
the involvement of the sympathetic nervous system
(SNS). In animal experiments for example, evidence sug-
gests that activating the reward system in mice modu-
lates the immune system and that ablation of SNS
nerves abolishes such modulation [57]. Such a conduit
between CNS and immune function may also exist in
human subjects. One study has shown that vagus nerve
stimulation impacted cytokine production and attenu-
ated the symptomatology of rheumatoid arthritis [58].
Other examples of such immune modulation include the
effect of placebo Echinacea on the common cold where
patients given placebo and active Echinacea had equal
reduction in symptomatology and duration compared to
those given no pills at all. For a subgroup of patients
who believed in Echinacea and received pills, duration of
colds was substantively shorter and less severe, regard-
less of whether the pills contained Echinacea [59].
Why might there have evolved an innate ability of
parts of the CNS to use higher cognitive judgement of a
situation the organism finds itself in to modulate seem-
ingly automatic processes such as immune regulation? If
one considers the considerable resources used in mount-
ing and modulating immune activity [60], the ability of
the CNS to judge the parsimonious use of such re-
sources makes sense. This in the light of the need for
differential immune responses in different situations
where differing demands on resources are being encoun-
tered. For example, up regulating inflammatory re-
sponses are more useful in situations of social isolation
whereas immune responses targeted at bacterial or viral
infections are ramped down under such circumstances
[61]. In addition, some circumstances including those
that constitute a threat to safety would not be the most
appropriate circumstances to rest, and recover or spend
valuable resources on costly immune marshalling. Mech-
anisms that allow conscious complex social cues con-
cerning present or near future circumstances of an
individual to influence physiological responses such as
immunity would then be evolutionarily advantageous.
This is further explored in section 5.0.
Motor function and performance
The influence of placebos in sport are only just begin-
ning to be explored. Emerging evidence suggests that
physical barriers to increased effort such as fatigue may
be determined centrally in the CNS and not in the per-
ipheral physiology. This leads to the idea that aspects of
conscious expectation similar to those described in anal-
gesia and immunity can also directly influence perform-
ance [62]. For example, deception of cyclists into
believing they were racing against previous trials despite
the trial demanding 2% greater power output than the
actual previous trials, showed that such subjects always
retained a metabolic reserve even during maximal time
trials and that this reserve could be accessed after decep-
tion. Early studies involving placebo effects on muscle
strength have shown that expectancy of receiving ana-
bolic steroids significantly improved performance in
weight lifters. Others have documented significant in-
creases in power output in cyclists who believed they
had ingested caffeine and that this was dose dependent
[63]. Research then is emerging that documents signifi-
cant and reproducible effects of placebo on performance
and is linked to the ability to regulate pace, dependent
upon CNS capacity, to cognitively predict the metabolic
demands of exertion against actual metabolic capacity
[64]. In this regard then, powerful cues similar to those
seen in clinical practice may underlie such observed
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effects where a belief that improved performance will
ensue post intervention.
The false dichotomy of specific versus nonspecific
Nonspecific effects of treatment are characterised as
those occurring incidentally outside the aim of the
primary treatment and are interwoven with the negative
semantics of the historical placebo. Placebo falls within
the remit of such effects and the cultural impact of
labelling treatment effects as nonspecific can be pro-
found. The recent increasingly demonized practice of
homeopathy for example has been dominated by the ac-
cusation that the clinical effects seen are nothing more
than nonspecific in nature and as such, indefensible as a
practice provided within the national healthcare system.
Much of the evidence does indeed suggest that homeo-
pathic approaches generate effects no greater than a pla-
cebo [65]. As another example, recent draft clinical
guidelines for Low back pain in the UK have excluded
acupuncture as a recommended modality precisely
because the effects are non-specific in nature. To quote;
“The GDG [Guideline Development Group] noted that
although comparison of acupuncture with usual care
demonstrated improvements in pain, function and
quality of life in the short term, comparison with sham
acupuncture showed no consistent clinically important
effect, leading to the conclusion that the effects of
acupuncture were probably the result of non-specific
contextual effects [66].
However, the crux of the matter (and often over-
looked) is how much effect does a placebo generate? To
speculate, if giving 100 patients a sugar pill in a context
that generated adequate relief of IBS symptoms in 60%
of patients, at a fraction of the cost of the standard
pharmaceutical approach and with few side effects and
near zero risk of harm, then arguments dismissing the
effect as merely non-specific and worthless seems short
sighted at the very least. Indeed, outside of speculation,
similar results were seen with acupuncture augmented
by positive language for IBS patients (63%) compared to
a no treatment waiting list (28%) [67]. Why then a rejec-
tion of such phenomena in some quarters? Is it that ac-
knowledgement of the efficacy of nonspecific effects
threatens the nature of clinical authority and potentially
in some eyes, undermines the cultural dominance of
orthodoxy with fears of unfettered unorthodoxy? While
such anxieties may be understandable to an extent, the
wholesale dismissal of the overt use of such contextual
factors as outlined in the CARe model might seem less
than justified.
It is increasingly clear from emerging research that
what is generating so called nonspecific effects is as
specific as the binding of a drug to a receptor. This
is exemplified by brain imaging studies that indicate
that the well characterised pathways underlying ex-
pectation based analgesia are used in both the en-
dogenous placebo response to pain and exogenous
opioid drug response to pain and are substantively
similar if not identical [68]. Indeed, evidence suggests
that a range of drugs that elicit their ‘specific’ effects
from analgesia to immune modulation do so by bind-
ing specifically to receptors on pre-existing neuro-
logical pathways that modulate the same activity that
the drug is designed to modulate. In other words,
much of the pharmacopeia specificity rides on the
back of pre-existing pathways that can be modulated
by contextual cues [69].
For contextually modulated analgesia, these neural
pathways extend from the prefrontal cortex where the
individual generates conscious understanding of con-
text and meaning and end in the periaqueductal gray.
Dominated by endorphin receptors, these networks,
through further neural loci, modulate the ascending
nociception signals generated by body tissue. Given
these similarities in the neural pathways underlying
both exogenous opioid drug based analgesia and
endogenous endorphin based placebo analgesia the
notion of specific and non specific based analgesia be-
comes meaningless. To illustrate, when an individual
is given an opioid based drug, the drug binds to re-
ceptors in an anatomically defined pain modulatory
pathway and alters the activity of this pathway in a
way that modulates the ascending nociceptive pain
signals. This is quintessential medicine, drug based,
molecularly specific, chemically and biologically char-
acterised action. When a clinician suggests that an
inert placebo pill is a powerful analgesic, the patients
understanding and expectation of pain relief triggered
by these contextual signals releases ‘innate’ endogen-
ous opioids (endorphins) that binds to receptors in
the same anatomically defined pain modulatory path-
way as above and alters the activity of this pathway
in a way that modulates the ascending nociceptive
pain signals [68]. This effect is called nonspecific,
merely a placebo, and constitutes the basis for exclu-
sion of a therapy if clinical trials indicate the efficacy
is no better than placebo, despite that effect being
large. Given that there is an iatrogenic epidemic of
addiction to opioids in the US [70], yet few if any
risks of addiction to ethically provided positive ex-
pectation as in CARe, how can this be justified? Fur-
thermore, how can one effect be characterised as
nonspecific and illegitimate and the other specific and
legitimate, when they act through precisely the same
biology using the same mechanism. This seems more
like a cultural problem than a scientific one.
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The science of clinician mediated innate healing:
why patients can’t do it alone
One key question that remains substantially unanswered
within the study of contextual factors and their ability to
modulate physiological processes centres on the appar-
ent inability for an individual to ‘placebo’ themselves.
Insights into an answer to this problem may provide a
generic neurobiological basis of clinical interventions ex-
emplified by the CARe paradigm presented here. This
includes the skilful construction of contextual ‘wrappers’
or envelopes, within which degrees of specific modalities
are embedded, forming the framework of skilled thera-
peutic and legitimate interventions.
To begin to explore answers to this question, it is im-
portant to consider a Darwinian context. Here the likely
importance of the CNS to judge the use of physiological
resources in the context of the circumstances the organ-
ism finds themselves, or anticipates to be in the near fu-
ture is a key component. One area that may inform such
a discussion is that of fatigue. Fatigue has been consid-
ered to be dominated by peripheral physiological factors,
that ultimately result in failure of one or more systems,
resulting in a physiological fatigue. However, a more re-
cent formulation, the central governor model (CGM),
invokes the idea of a central governor that through an-
ticipatory psychological judgement, determines the pace
needed to complete a physical task such as running,
centrally generating a strong perception of fatigue if pace
or distance is exceeded [70, 71].
Noakes [72] who originated this model suggests that
factors integrated prior to a race to inform this predict-
ive capacity may include “…the athlete’s physiological
state at the start of exercise; the expected distance or
duration of the intended exercise bout; the degree of pre-
vious experience that the athlete has, especially in the
specific activity that is being undertaken; the athlete’s
level of motivation, which will be influenced by the level
of external competition and the importance the athlete
ascribes to the event; and the athlete’s level of self-belief”.
Emerging evidence [73, 74] supports such a model, in
the way athletes judge pacing as a complex interaction
of emotions and expectations integrated with peripheral
changes in muscles to support homeostasis during phys-
ical exercise. This makes evolutionary sense in that such
an individual is protected from the effects of exhausting
all resources while in an environment or an anticipated
near future where additional resources may be called
upon by some unpredictable event (e.g., encountering a
lion at the end of running down an antelope precipitat-
ing the necessity of sprinting away) [75]. The idea of
CNS judgement of circumstances within which re-
sources can be appropriately spent, can be extend to an-
swer the question why humans cannot self-generate
strong placebo effects.
Nicholas Humphrey [75] first postulated the existence
of a ‘health governor’ in 2002. This is similar but not
identical to Noakes’ CGM where the CNS judgment of
resource use is linked to fatigue [72]. In contrast,
Humphrey envisaged a contextually driven process mak-
ing top down predictions of the likely circumstances
within which extensive resource use, such as those asso-
ciated with increased marshalling of immune function
[60], was likely to outweigh the downside of such re-
source use. Here the switching on of ‘innate healing pro-
cesses’ were done only in the right conditions where
other constraints such as food availability and environ-
mental threats were likely to be minimised in the near
future. This ancient ability would have initially been lim-
ited to coarse grained predictions at an unconscious
level perhaps using light/dark changes to anticipate
spring or winter [76].
Recently however, these authors and others [77, 78]
have expanded this model to provide a comprehensive
and convincing argument for the presence of additional
input as provided by the evolution of higher cognitive
function and social sharing of knowledge in humans.
This system allows vastly improved predictions of the
near future and could, in addition to the economic argu-
ment presented by these authors, be expanded to in-
clude the highly social nature of primates. This may help
to explain why the contextual inclusion of powerful so-
cial figures such as clinicians, may be able to trigger
hope of a ‘spring’ as opposed to a ‘winter’ and marshal
self-healing.
In this model, one might envisage that the triggering
of resources needed for recovery and rest are most
inappropriate when a highly social animal like a primate
is alone. In these circumstances vigilance and fight-flight
are potentially more important with recovery being de-
layed or attenuated until cues indicate a degree of safety
and protection are likely to be present and ongoing in
the near future. For intensely social species such as
homo sapiens these signals are likely to be most strongly
conveyed by the presence of the family or kin group. For
primates, cues such as touch through grooming may be
additionally powerful signals of safety. Ultimately,
grooming and or attentiveness by the alpha animal
would be the strongest cues that the near future is likely
to be one where spending expensive biological resources
on recovery will result in more benefit than harm. In
these circumstances it is envisaged that the CNS ‘health
governor’ initiates a number of centrally determined
physiological modulations, including pain, immune func-
tion and potentially others that switch the animal into
recovery mode as opposed to survival. This idea posits
grooming and attention as elements of prototypical
medicine and socially elevated groomers as prototypical
clinicians. Indeed, this may be why health professions
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taking on board the plumage of the culturally dominant
clinical paradigm (titles, clothing, language, context)
elicit powerful contextual triggers that generate innate
modulation of health states.
The predictions of such a model are intriguing. For
example, one might suggest that there are three broad
contextual components that may interact: physical
signals (touch being prototypical), verbal cues, and
environmental cues. In addition, the impact of these
factors may be modulated by the degree of cultural
authority that the individual is perceived as possessing
and this may be signalled by the cultural attributes
that serve to engender authority and trust [79]. This
may be summarised in Fig. 1.
In addition, increasing physical invasiveness (either
perceived or real) has increased impact on modulation
of the contextual effect (for example analgesia). Specu-
lating in the arena of manual therapy, touch through
manipulation to injection may be having a more power-
ful effect of pain modulation within the correct delivery
of the other contextual domains (Fig. 2). In support of
such a conjecture such grading of effects as generated by
contextual factors has previously been documented
[80–82]. For example, needle acupuncture, has been
shown to be more effective than other less invasive
procedures [82]. Furthermore, combined chiropractic
interventions have been shown to be slightly better at
improving acute low back pain and disability in the short
term, and pain in the medium term, than less “invasive”
modalities such as massage or stretching exercises [83].
This model predicts a number of testable research
questions.
1. In the context of manual therapy, do soft tissue
interventions alone have smaller effect sizes in low
back pain patients than those seen in manipulation
and facet injection?
2. Furthermore, do casually dressed and uncertain
chiropractors generate smaller analgesic effects than
those in a white coat and/or proclaiming certainty
about the efficacy of the treatment?
3. Does delivery of care in a clinically designed aesthetic
chiropractic setting generate better analgesic effects
than those delivered in the patient’s own home.
4. Does a comparison of strongly positive verbal cueing
as compared to neutral verbal cueing produce increased
benefit in chiropractic settings?
This model also suggests that there may be combina-
tions of contextual factors within these domains that are
more or less effective. For example, it is already known
that verbal cues can modulate the effect of both drug
and placebo effectiveness in reducing the severity of mi-
graine [80] and in modulating analgesia in acupuncture
[84]. Lastly, there is a possibility that different subgroups
of patients may be more or less amenable to various
combinations of contextual factors including the timing
of such factors during the course of a condition. Indeed,
evidence is already emerging regarding genetic predispo-
sitions to contextually induced analgesia [85].
Taken together, the CARe model and the preceding
summary of research provides an argument for an ap-
proach to clinical care that aims to maximise through de-
tailed understanding of combinations of contextual factors
and targeting of patients, the recovery or management of
a range of conditions in addition to those associated with
musculoskeletal (MSK) pain. Knowledgeable and judicious
use of these factors in the construction of a therapeutic
structure can generate powerful cues that support an in-
terpretation by the patients ‘health governor’ that safety
and care will be available in the predicted near future.
Within these environments, intrinsic recuperative mecha-
nisms including pain and immune modulation can be
switched on by anthropologically and evolutionary in-
formed environmental, verbal and physical signals as de-
livered in a cultural context. These processes are in turn
Fig. 1 Three component model of contextual factors modulated by
cultural authority
Fig. 2 Increased physical intervention enhances contextual effects
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controlled by CNS based networks/pathways that are inte-
grated with higher cognitive and learned processes that
anticipate appropriate use of biological resourcing. Skilful
delivery of such care, being as it is associated with recov-
ery, should then be couched in a language far removed
from the traditional polemic of placebo.
CARe as described here could in the future constitute
a shift in the false dichotomy between specific and non-
specific therapeutic effects and the policy implications
therein underpinned as they are by neurobiological and
physiological science. Such an understanding may pro-
vide the foundations of increasing acceptance of these
skills and the effects they generate as legitimate thera-
peutic intervention in addition to others, or in and of it-
self. A word of caution. Ethical issues remain [13, 86]
regarding deception and the fact that placebos rarely
cure, although a recent study indicated open placebo
without deception to provide additional effectiveness
over and above normal care in attenuating symptoms in
low back pain patients [87]. Notwithstanding, clear
boundaries would be imperative with a focusing of such
care on ostensibly non-life threatening conditions or the
sequelae of other conditions such as chronic pain [88].
In addition, embracing such a different view of what le-
gitimate treatment constitutes, may be a challenge not
only in some of the manual therapeutic professions but
also to medicine itself. In the end, however, the welfare
of the patient and best practice as increasingly and
rightly centred on the needs and experience of patients
may allow a re-evaluation of how legitimate clinical care
is described and in what capacity it is best delivered.
Conclusion
This paper introduces CARe as a new descriptive model
of the power of contextual factors and their effects on
analgesia, immune and motor modulation in MSK
conditions.
Evidence has mounted over the last decade to support
the ability of the CNS to judge the context of a clinical
encounter, what such contextual cues imply about the
predicted near future, biological resource use and the
impact of such judgements on physiological processes
through expectation and classical conditioning mecha-
nisms. This emerging understanding could provide a sci-
entific basis for a proportion of the observed MSK
effects and much of non-MSK effects seen in chiroprac-
tic patients undergoing chiropractic care. Indeed, a re-
cent study comparing an effective sham [89] with spinal
manipulation as guided by Gonstead methodology in mi-
graine patients concluded that the positive effects in the
manipulation group were the same as in the sham
group, both groups better than the control group, and
were likely due to a placebo response [90].
Professional anxieties understandably exist and the pe-
jorative language of placebo is an unhelpful and inaccur-
ate way to describe and judge these effects creating as
they do a viewpoint that relegates such skilled construc-
tion of therapeutic encounters to no more than
subterfuge or fraud. We present a contrasting view that
suggest these powerful and clinically important effects
should be further investigated, maximised and embraced
by all healthcare professions where the nature of patient
complaints is most benefited by such contextually laden
care, particularly chronic pain [89]. In addition, the need
for a caring, highly knowledgeable and skilful clinician
to enable individuals to access these innate healing sys-
tems suggests an increasing imperative to embed aspects
of models such as CARe in clinical encounters and clin-
ical education while elucidating more clearly the thera-
peutic components through clinical research.
The CARe approach should be an essential and power-
ful therapeutic tool that is central to the chiropractic
clinical encounter and may provide a framework for the
profession to engage in scientific investigation and de-
bate around such effects and in so doing relinquish un-
necessary adherence to outmoded and non-evidenced
paradigms as explanations for observations made in clin-
ical practice.
Much research still needs to be carried out to begin to
uncover the precise nature of contextual factors and
their interrelationships within the typical chiropractic
encounter. Nevertheless, it is hoped that the CARe para-
digm may provide an evidence based framework for
legitimising skilful and patient centred application of
contextual healing within the chiropractic profession
and across health care in general.
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